

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	
				09/693,754	
				Filing Date	
				2000-10-20	
				First Named Inventor	
				N. Berinstein	
Art Unit				1633	
Examiner Name				Anne Marie Sabrina Wehbe	
(Use as many sheets as necessary)					
Sheet	1	of	3	Attorney Docket No: 13115	

US PATENT DOCUMENTS

Examiner Initial *	Cite No	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	5,093,258	1992-03-03	Cohen, et al.	Entire document
	A2	5,141,742	1992-08-05	Brown, et al.	Entire document
	A3	5,342,774	1994-08-30	Boon, et al.	Entire document
	A4	5,405,940	1995-04-11	Boon, et al.	Entire document
	A5	5,462,871	1995-10-31	Boon-Faulier, et al.	Entire document
	A6	5,505,941	1996-04-09	Paoletti, E.	Entire document
	A7	5,831,016	1998-11-03	Wang, et al.	Entire document
	A8	5,840,839	1998-11-24	Wang, et al.	Entire document
	A9	5,844,075	1998-12-01	Kawakami, et al.	Entire document
	A10	5,874,560	1999-02-23	Kawakami, et al.	Entire document
	A11	5,972,597	1999-10-26	Paoletti, et al.	Entire document
	A12	6,001,349	1999-12-14	Panicali, et al.	Entire document
	A13	6,045,802	2000-04-04	Schlom, et al.	Entire document
	A14	6,083,703	2000-07-04	Wang, et al.	Entire document
	A15	6,087,110	2000-07-11	Wang, et al.	Entire document
	A16	6,127,116	2000-10-03	Rice, et al.	Entire document
	A17	6,132,980	2000-10-17	Wang, et al.	Entire document
	A18	6,319,496	2001-11-20	Panicali, et al.	Entire document
	A19	6,340,462	2002-01-22	Paoletti, et al.	Entire document
	A20	6,407,063	2002-06-18	Luiten, et al.	Entire document
	A21	6,531,451	2003-03-11	Chaux, et al.	Entire document
	A22	6,548,068	2003-04-15	Schlom, et al.	Entire document
	A23	6,558,671	2003-05-06	Slingluff, et al.	Entire document
	A24	6,693,086	2004-02-17	Dow, et al.	Entire document
	A25	6,699,475	2003-05-06	Slingluff, et al.	Entire document
	A26	6,756,038	2004-06-29	Schlom, et al.	Entire document
	A27	6,780,407	2004-08-24	Paoletti, et al.	Entire document
	A28	6,710,172	2004-03-23	Chaux, et al.	Entire document
	A29	6,805,869	2004-10-19	Gao, Y.	Entire document
	A30	6,893,869	2005-05-17	Schlom, et al.	Entire document
	A31	6,951,917	2005-10-04	Topalian, et al.	Entire document
	A32	6,969,609	2005-11-29	Schlom, et al.	Entire document
	A33	7,232,887	2007-06-19	Kawakami, et al.	Entire document
	A34	2003/0082150	2003-05-01	Boon-Faulier, et al.	Entire document

EXAMINER

DATE CONSIDERED

(Substitute Disclosure Statement Form (PTO) 1448A)

* EXAMINER: Indicate if reference is considered, whether or not citation is in accordance with MPEP 809.09. Do not cite through citation if not in accordance and not re-examined. Indicate if this form with next contribution to applicant's Applicant's unique citation designation number (optional). Applicant is to place a check mark next to English language translation is allowed.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AW/ (11/10/2009)

Substitute for form 1449A/PIC

Use as many sheets as necessary.

Complete if Known

Application Number	09/693,754
Filing Date	2000-10-20
First Named Inventor	N. Berinstein
Art Unit	1633
Examiner Name	Anne Marie Sabrina Webber

Attorney Docket No: 13115

Sheet 2 of 3

Examiner Initial *	Cite No	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A35	2004/015686A1	2004-08-12	Figdor, et al.	Entire document
	A36	2005/0136066A1	2005-06-23	Guo, Y.	Entire document
	A37	09/693,755	N/A	Bernstein, et al.	Entire document

FOREIGN PATENT DOCUMENTS						T ²
Examiner Initials *	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	B1	WO 96/11279	1995-10-02	The Govt. USA	Entire document	
	B2	WO 99/40188	1999-08-12	Cabezon, et al.	Entire document	
	B3	WO 99/46992	1999-09-23	Kaplan, et al.	Entire document	
	B4	WO 01/30847	2001-05-03	Aventis Pasteur Limited	Entire document	

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	COX, et al. Identification of a Peptide Recognized by Five Melanoma-Specific Human Cytotoxic T Cell Lines. Science, vol. 264: 716-719 (1994)	
	C2	HODGE, et al. Diversified Prime and Boost Protocols Using Recombinant Vaccine Virus and Recombinant Non-Replicating Avian Pox Virus to Enhance T-Cell Immunity and Antitumor Responses. Vaccine, vol. 15, issue 6/7, pp. (1997)	
	C3	HURPIN, et al. The Mode of Presentation and Route of Administration Are Critical for the Induction of Immune Responses to p53 and Antitumor Immunity. Vaccine, vol. 16, no. 2/3, pp. 208-215 (1998)	
	C4	IRVINE, et al. Recombinant Virus Vaccination Against "Self" Antigens Using Anchor-Fixed Immunogens. Cancer Res., vol. 59: 2536-2540 (1999)	
	C5	KAWAKAMI, et al. Identification of a Human Melanoma Antigen Recognized by Tumor-Infiltrating Lymphocytes Associated with in vivo Tumor Rejection. Proc. Natl. Acad. Sci. USA, vol. 91, pp. 6458-6462 (1994)	
	C6	KUNDIG, et al. Fibroblasts as Efficient Antigen-Presenting Cells in Lymphoid Organs. Science, vol. 268, pp. 1343-1347 (1995)	

DATE CONSIDERED

Substrate Reaction: Methyl-oxo-Formate (MFO) 1:1:10

• **EXAMINER:** Initial if reference considered, whether or not citation is in conformance with NRP 6.5. Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AW/ (11/10/2009)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/693,754
				Filing Date	2000-10-20
				First Named Inventor	N. Berinstein
				Art Unit	1633
				Examiner Name	Anne Marie Sabrina Wehbe
(Use as many sheets as necessary)					
Sheet	3	of	3	Attorney Docket No: 13115	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C7	LEHNER, et al. Targeted Lymph Node Immunization with Simian Immunodeficiency Virus p27 Antigen to Elicit Genital, Rectal, and Urinary Immune Responses in Nonhuman Primates. <i>J. Immunol.</i> Vol. 153: 1858-1868 (1994)	
	C8	LEHNER, et al. Protective Mucosal Immunity Elicited by Targeted Ilia Lymph Node Immunization with a Subunit SIV Envelope and Core Vaccine in Macaques. <i>Nat. Med.</i> Vol. 2, No. 7, pp. 767-775 (1996)	
	C9	LEHNER, et al. The Effect of Route of Immunization on Mucosal Immunity. <i>J. Infect. Dis.</i> 179(supp. 3), pp. S489-S492 (1999)	
	C10	MACKENSEN, et al. Homing of Intravenously and Intralymphatically Injected Human Dendritic Cells Generated in vitro from CD34+ Hematopoietic Progenitor Cells. <i>Cancer Immunol. Immunother.</i> Vol. 48, pp. 118-122 (1999)	
	C11	NESTLE, et al. Vaccination of Melanoma Patients with Peptide- or Tumor Lysate-Pulsed Dendritic Cells. <i>Nature Med.</i> Vol. 4, No. 3, pp. 328-332 (1998)	
	C12	PARKHURST, et al. Improved Induction of Melanoma-Reactive CTL with Peptides from Melanoma Antigen gp100 Modified at HLA-A0201-Binding Residues. <i>J. Immunol.</i> Vol. 157, no. 6, pp. 2539-48 (1996)	
	C13	POND, et al. Interactions Between Adipose Tissue Around Lymph Nodes and Lymphoid Cells in vitro. Vol. 36, pp. 2219-2231 (1995)	
	C14	PUNT, et al. Biodistribution and Vaccine Efficiency of Murine Dendritic Cells are Dependent on the Route of Administration. <i>Cancer Res.</i> Vol. 59, pp. 3340-3345 (1999)	
	C15	RAO, et al. Partial Characterization of Two Subpopulations of T4 Cells Induced by Active Specific Intralymphatic Immunotherapy (ASILI) in Melanoma Patients. Vol. 27, abstract 1290 (1986)	
	C16	RESTIFO, et al. Antigen Processing In Vivo and the Elicitation of Primary CTL Responses. <i>J. Immunol.</i> 154: 4414-4422 (1995)	
	C17	SALGALLER, et al. Immunization Against Epitopes in the Human Melanoma Antigen gp100 Following Patient Immunization with Synthetic Peptides. <i>Cancer Res.</i> Vol. 56, pp. 4749-4757 (1996)	
	C18	WIRA, et al. Effect of Uterine Immunization and Oestradiol on Specific IgA and IgG Antibodies in Uterine, Vaginal and Salivary Secretions. <i>Immunology</i> , vol. 68, pp. 24-30 (1989)	
	C19	WIRA, et al. Specific IgA and IgG Antibodies in the Secretions of the Female Reproductive Tract: Effects of Immunization and Estradiol on Expression of this Response in vitro. <i>J. Immunol.</i> Vol. 138, No. 12, pp. 4159-4164 (1987)	
	C20	WOLFEL, et al. Two Tyrosine Nonapeptides Recognized on HLA-A2 Melanomas by Antitumor Cytolytic T Lymphocytes. <i>Eur. J. Immunol.</i> Vol. 24, pp. 759-764 (1994)	

EXAMINER

DATE CONSIDERED

(Substitute Disclosure Statement Form (PTT-1448))

*EXAMINER: Initials reflecting consideration, whether or not citation is in accordance with MPEP 905. Drawn through citation if not in, performance and not notated, brevity only of this form with most consideration to applicant's Applicant's unique situation (signature number optional) / Applicant's to place a check mark next to English language translation is attached

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AW/ (11/10/2009)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	09/693,754
				Filing Date	2000-10-20
				First Named Inventor	N. Berinstein
				Art Unit	1633
				Examiner Name	Anne Marie Sabrina Wehbe
Sheet	4	of	3	Attorney Docket No: 13115	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C21	XIANG, et al. An Autologous Oral DNA Vaccine Protects Against Murine Melanoma. Proc. Natl. Acad. Sci. USA, vol. 97, no. 10, pp. 5492-5497 (2000)	
	C22	ZAREMBA, et al. Identification of an Enhancer Agonist Cytotoxic T Lymphocyte Peptide from Human Carcinoembryonic Antigen. Cancer Res. Vol. 57, pp. 4570-4577 (1997)	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AW/ (11/10/2009)

EXAMINER /Anne Marie Wehbe/ (11/10/2009)

DATE CONSIDERED

11/10/2009

(Substitute Disclosure Statement Form (PTO-1449))

* EXAMINER: Indicate if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not reconsidered. Inventor's reply of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language translation is attached.